Clinical Trial Update: Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of bevacizumab and pegylated interferon alfa-2b in patients with metastatic or unresectable gastrointestinal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoid Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor | Phase 2 | Status: COMPLETED